| Withdrawn | Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis NCT05060380 | University of Alabama at Birmingham | N/A |
| Not Yet Recruiting | The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation NCT07406685 | National Taiwan University Hospital | Phase 4 |
| Not Yet Recruiting | Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females NCT07365514 | University of Connecticut | Phase 1 |
| Not Yet Recruiting | AGE Burden and Response to Antiresorptive Therapy in Osteoporosis NCT07329543 | Bursa City Hospital | — |
| Recruiting | StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis NCT06767150 | University Hospital, Toulouse | Phase 4 |
| Active Not Recruiting | A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) NCT06577935 | Angitia Biopharmaceuticals | Phase 2 |
| Completed | Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteopor NCT06264401 | Cairo University | N/A |
| Completed | A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fractur NCT06079476 | Amgen | Phase 4 |
| Recruiting | Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis NCT05902078 | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Phase 4 |
| Completed | Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women NCT05630768 | Dong-A ST Co., Ltd. | Phase 4 |
| Unknown | Efficacy and Safety of Minodronate in Patients With Low Back Pain NCT05645289 | Peking University Third Hospital | Phase 4 |
| Completed | Impact of Ultraviolet Radiation on Bone Density and Muscle Strength in Postmenopausal Women NCT05650437 | Cairo University | N/A |
| Unknown | Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis NCT05433207 | Chugai Pharmaceutical | — |
| Completed | A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® NCT05405725 | Enzene Biosciences Ltd. | Phase 3 |
| Unknown | Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis NCT05278338 | Shanghai JMT-Bio Inc. | Phase 2 |
| Active Not Recruiting | Anabolic Therapy in Postmenopausal Osteoporosis NCT05010590 | Massachusetts General Hospital | Phase 4 |
| Unknown | Pravastatin Reduces Acute Phase Response of Zoledronic Acid NCT04719481 | Peking University Third Hospital | Phase 4 |
| Unknown | Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid NCT04719650 | Peking University Third Hospital | Phase 4 |
| Completed | Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis NCT05087030 | Gedeon Richter Plc. | Phase 3 |
| Unknown | Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adu NCT04940845 | Shanghai Hansoh Biomedical Co., Ltd | Phase 1 |
| Completed | Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk NCT04431960 | University of Connecticut | Phase 1 |
| Completed | Compare the Agility Exercise and Resistance Exercise on Physical Function and Stability in Osteoporotic Women NCT06457308 | Tainan Hospital, Ministry of Health and Welfare | N/A |
| Completed | Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients NCT05346419 | Hospital Regional 1o de Octubre | N/A |
| Completed | A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Wom NCT04934072 | Fresenius Kabi SwissBioSim GmbH | Phase 3 |
| Completed | Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment NCT05347082 | Hospital Regional 1o de Octubre | N/A |
| Completed | Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . NCT04591275 | Shanghai Biomabs Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Translation and Cross -Cultural Validation of ECOS-16 Questionnaire in Urdu Language NCT04873960 | Riphah International University | — |
| Completed | A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis NCT04664959 | Samsung Bioepis Co., Ltd. | Phase 3 |
| Completed | How Vertebral Fractures Effect Balance In Postmenopausal Women NCT06502301 | Istanbul University - Cerrahpasa | — |
| Completed | High Intensity Multi-Modal Exercise Training in Postmenopausal Women NCT04653350 | Riphah International University | N/A |
| Completed | Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults NCT04747392 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 |
| Completed | Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients NCT04702204 | Nigde Omer Halisdemir University | — |
| Completed | Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation NCT04338529 | 251 Hellenic Air Force & VA General Hospital | — |
| Completed | Prevention of Early Postmenopausal Bone Loss With Lactobacillus Reuteri NCT04169789 | Sahlgrenska University Hospital | N/A |
| Completed | Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration NCT04026256 | Massachusetts General Hospital | Phase 4 |
| Completed | Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteo NCT04064411 | Radius Health, Inc. | Phase 3 |
| Completed | Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers NCT03925051 | Shanghai Biomabs Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Quality of Life in Postmenopausal Women With Osteoporosis NCT03970902 | University Ghent | — |
| Unknown | A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk NCT05060406 | Luye Pharma Group Ltd. | Phase 3 |
| Unknown | Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk NCT04128163 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Micro NCT04366726 | Radius Health, Inc. | Phase 1 |
| Unknown | G56W1 in Women With Postmenopausal Osteoporosis NCT03720886 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Association of Serum Ferritin and Bone Mineral Density With Bone Metabolism in Chinese Healthy Postmenopausal NCT03512743 | Second Affiliated Hospital of Soochow University | — |
| Unknown | The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP) NCT02854722 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Completed | MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis NCT03472846 | Medical University of Vienna | Phase 4 |
| Completed | A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis NCT02791516 | Amgen | Phase 3 |
| Unknown | CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome NCT02981732 | xuhuijuan | N/A |
| Active Not Recruiting | Dried Plums and Bone Health in Postmenopausal Women NCT02822378 | Penn State University | N/A |
| Completed | Moringa Oleifera on Bone Density NCT03026660 | Appalachian State University | N/A |
| Completed | Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation NCT02499237 | 424 General Military Hospital | Phase 4 |
| Completed | A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forte NCT02478879 | Zosano Pharma Corporation | Phase 1 |
| Completed | Denosumab and Teriparatide Study (DATA-HD and DATA-EX) NCT02176382 | Massachusetts General Hospital | Phase 4 |
| Completed | A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Pos NCT02157948 | Amgen | Phase 3 |
| Completed | Study on the microRNA Expression Level in Postmenopausal Osteoporosis NCT02128009 | Fujian Academy of Traditional Chinese Medicine | — |
| Completed | A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporos NCT02016716 | Amgen | Phase 3 |
| Completed | An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Wom NCT01796301 | Amgen | Phase 3 |
| Completed | Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption NCT01750086 | Massachusetts General Hospital | Phase 4 |
| Completed | Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis NCT01657162 | Radius Health, Inc. | Phase 3 |
| Completed | VERtebral Fracture Treatment Comparisons in Osteoporotic Women NCT01709110 | Eli Lilly and Company | Phase 4 |
| Withdrawn | Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) NCT01552122 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bo NCT01572545 | Aristotle University Of Thessaloniki | N/A |
| Completed | Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis NCT01575834 | Amgen | Phase 3 |
| Unknown | Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1 NCT01834105 | Fujian Academy of Traditional Chinese Medicine | Phase 2 |
| Completed | Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis NCT01668589 | Amgen | — |
| Completed | Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml NCT01348243 | Chiesi Farmaceutici S.p.A. | Phase 3 |
| Completed | Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausa NCT01343004 | Radius Health, Inc. | Phase 3 |
| Completed | Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women NCT01321723 | Unigene Laboratories Inc. | Phase 2 |
| Completed | Open-label Study to Evaluate the Effect of MBP-80 on Bone Remodelling NCT01501344 | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc. | N/A |
| Completed | The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam NCT01221727 | Amgen | Phase 1 |
| Completed | Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan NCT02422069 | Hoffmann-La Roche | — |
| Completed | A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis NCT01128257 | Hoffmann-La Roche | — |
| Completed | Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis NCT01406613 | Sheffield Teaching Hospitals NHS Foundation Trust | — |
| Completed | A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausa NCT00909961 | Novartis Pharmaceuticals | Phase 3 |
| Completed | MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonat NCT00996801 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis NCT01544894 | University of Valencia | Phase 4 |
| Completed | A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated NCT00890981 | Amgen | Phase 3 |
| Completed | A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally NCT00936897 | Amgen | Phase 3 |
| Completed | Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density NCT00896532 | Amgen | Phase 2 |
| Completed | A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Ost NCT00887965 | Amgen | Phase 2 |
| Completed | Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women NCT00918749 | Warner Chilcott | Phase 2 |
| Completed | Epidemiology, Identification Rate and Treatment Penetration of Osteoporotic Vertebral Fractures in Switzerland NCT02234414 | Prof. Dr. med. Kurt Lippuner | — |
| Completed | Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis NCT00745121 | Dentsply Sirona Implants and Consumables | N/A |
| Completed | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Post NCT00676312 | Novartis | Phase 1 |
| Completed | A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis NCT00541658 | Warner Chilcott | Phase 3 |
| Terminated | A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) NCT00529373 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women NCT00578981 | Mayo Clinic | N/A |
| No Longer Available | A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis. NCT00493532 | Hoffmann-La Roche | — |
| Completed | Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Hea NCT00395395 | Novartis | Phase 1 |
| Completed | Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation NCT00381251 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Study of Transitioning From Alendronate to Denosumab NCT00377819 | Amgen | Phase 3 |
| Completed | Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women NCT00411125 | Novartis | Phase 1 |
| Completed | A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. NCT00545051 | Hoffmann-La Roche | Phase 4 |
| Completed | A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Deno NCT00293813 | Amgen | Phase 2 |
| Completed | A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Support NCT00545363 | Hoffmann-La Roche | Phase 4 |
| Completed | BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteop NCT00545909 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Monthly Risedronate for Osteoporosis NCT00247273 | Warner Chilcott | Phase 3 |
| Completed | Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial NCT00239629 | Eli Lilly and Company | Phase 4 |
| Completed | Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women NCT00165698 | Eisai Co., Ltd. | Phase 3 |
| Completed | PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia NCT02598453 | Hoffmann-La Roche | Phase 4 |
| Completed | Study of Investigational Drug in Osteoporosis (MK-0217-908) NCT00092053 | Organon and Co | Phase 3 |
| Completed | Effects of Teriparatide in Postmenopausal Women With Osteoporosis NCT00079924 | Eli Lilly and Company | Phase 4 |
| Completed | Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis NCT00091793 | Amgen | Phase 3 |
| Completed | A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteope NCT02604836 | Hoffmann-La Roche | Phase 4 |
| Completed | Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women NCT00086619 | Massachusetts General Hospital | Phase 2 |
| Completed | A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis NCT02598440 | Hoffmann-La Roche | Phase 4 |
| Completed | Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or R NCT00778154 | Warner Chilcott | — |
| Completed | Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis. NCT00238745 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 |
| Completed | Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO NCT00577421 | Warner Chilcott | Phase 3 |
| Completed | A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219) NCT00092027 | Organon and Co | Phase 3 |
| Completed | A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopaus NCT00092014 | Organon and Co | Phase 3 |
| Completed | Prevention of Osteoporosis in Breast Cancer Survivors NCT00567606 | University of Nebraska | N/A |